**Appendix No. 17 - Numbers and Percentages of Cancer Patients discussed in Tumor Boards**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | 1 | 2 | 3 | 4 | 5 | 6 |
| Disease site (without pediatric tumors) according to the list of tumor localizations used in the analysis of the Robert Koch Institute ('Krebs in Deutschland; 2013) modified on the basis of the National Cancer Certification Program 2015 | ICD-10 Code | Number of all cancer patients treated in the cancer center in 2020 | Patients discussed in tumor board | %columns2/1 | Number of cancer patients newly diagnosed in 2020 | Patientsdiscussed in tumor board | %column5/4 |
| **A.** |
| *Head and Neck***Stoma/Pharynx** |  |
| C00-14 |  |  |  |  |  |  |
| **Larynx** | C32 |  |  |  |  |  |  |
| *Upper GI Tract***Esophagus**  |  |
| C15 |  |  |  |  |  |  |
| **Stomach**  | C16 |  |  |  |  |  |  |
| **Intestine** | C18-21 |  |  |  |  |  |  |
| *Liver/Gall Bladder***Liver**  |  |
| C22 |  |  |  |  |  |  |
| **Gall Bladder** | C23-24 |  |  |  |  |  |  |
| **Pancreas**  | C25 |  |  |  |  |  |  |
| **Lung**  | C33-34 |  |  |  |  |  |  |
| **Malignant Melanoma**  | C43 |  |  |  |  |  |  |
| **Bone, Articular Cartilage, Connective and Soft Tissue** | C40-41,C45-49 |  |  |  |  |  |  |
| *Breast/DCIS***Ductal Carcinoma in Situ (DCIS)** |  |
| D05 |  |  |  |  |  |  |
| **Breast** | C50 |  |  |  |  |  |  |
| **Vulva** | C51 |  |  |  |  |  |  |
| **Cervix** | C53 |  |  |  |  |  |  |
| **Uterus** | C54-55 |  |  |  |  |  |  |
| **Ovary**  | C56 |  |  |  |  |  |  |
| **Prostate**  | C61 |  |  |  |  |  |  |
| **Testes**  | C62 |  |  |  |  |  |  |
| **Kidney**  | C64 |  |  |  |  |  |  |
| **Urinary Bladder** | C67 |  |  |  |  |  |  |
| **Central Nervous System** | C70-72**\*** |  |  |  |  |  |  |
| **Thyroid** | C73 |  |  |  |  |  |  |
| **Morbus Hodgkin** | C81 |  |  |  |  |  |  |
| **Non-Hodgkin Lymphomas** | C82-85 |  |  |  |  |  |  |
| **Plasmocytoma** | C90 |  |  |  |  |  |  |
| **Leukemias** | C91-95 |  |  |  |  |  |  |
| **Other Hematological Malignancies** | C86-88, C96 |  |  |  |  |  |  |
| **TOTAL (A)** |  |  |  |  |  |  |  |
| **B.** |
| **Others\*\* (Examples):** |  |  |  |  |  |  |  |
| Other Malignant Neoplasms of the Skin | C44 |  |  |  |  |  |  |
| Pediatric Tumors (Patients < 18 y.)**\*\*\*** |  |  |  |  |  |  |  |
| **TOTAL (A. + B.)** |  |  |  |  |  |  |  |

**In case of a CCC Consortium, please provide the appendix for each individual partner site as well as for the total consortium.**

**Column 1:** Number of all cancer patients treated in the cancer center in 2020. Please transfer the numbers from appendix 4/column 1.

**Column 2:** How many of the column 1 patients were discussed in tumor boards in 2020?Do not include any patient more than once unless he/she was treated for more than one malignancy in 2020.

**Column 3:** Percentage of cancer patients discussed in tumor boards (column 2/1).

**Column 4:** Number of cancer patients newly diagnosed in 2020. Please transfer the numbers from appendix 4/column 2.

**Column 5:** How many of the column 4 patients were discussed in tumor boards in 2020?Do not include any patient more than once unless he/she was treated for two malignancies in 2020.

**Column 6:** Percentage of cancer patients discussed in tumor boards (column 5/4).

\*Further CNS tumors which are requested within the 'National Cancer Certification Program' ('Erhebungsbogen Neuroonkologische Tumoren', Chapter 1.2.1; ICD-10: C75.1-3, D32, D33.3, D35.2-4; primary CNS lymphomas) can be listed under 'Others'.

\*\*Disease sites which are not listed above, can be indicated under 'Others', but must not be counted among 'Total' (A).

\*\*\*Pediatric tumors may only be listed here and must not be counted under 'Total' (A).